Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (NASDAQ: GEHC) introduced the new LOGIQ e family, comprising LOGIQ e Xi and LOGIQ e Si, laptop-sized ultrasound systems designed to deliver console-level imaging across multiple care settings. The systems target applications such as emergency medicine, critical care, musculoskeletal, rheumatology and anesthesiology.
According to GE HealthCare, LOGIQ e Xi is the premium model, adding AI-powered tools like Nerveblox and MSK Go, B-Flow blood flow imaging, Speckle Reduction Imaging-HD, Automated Function Imaging and SonoBiometry. Both systems can integrate Verisound cloud tools, and LOGIQ e Xi supports Vscan Air probe compatibility. The latest LOGIQ e systems are 510(k) cleared and CE Marked.
GE HealthCare (NASDAQ: GEHC) launched Invenia ABUS Prime, an automated 3D breast ultrasound system, and ABUS StreamVue, a zero-footprint browser-based reading solution recently cleared via U.S. FDA 510(k) and granted CE Marking, expanding its breast imaging portfolio for women with dense breasts.
Invenia ABUS Prime, which is among the first U.S. installations at BeSound in Los Angeles, is designed to standardize supplemental screening alongside mammography, support multi-site workflows, and enhance patient comfort. The system features the cSound Imageformer, Verisound AI tools, Fast Scan for up to 40% faster exams, a new Reverse Curve transducer, and selectable compression levels.
AI-supported reading via QVCAD is reported to cut reading time by 33% and reach up to 93% lesion-detection sensitivity. ABUS StreamVue, powered by Candelis and delivered in collaboration with Candelis, enables remote ABUS exam review, adaptable licensing, and simpler deployment across enterprise imaging networks.
According to GE HealthCare, Invenia ABUS Prime holds U.S. FDA Premarket Approval and CE Marking, while ABUS StreamVue is FDA 510(k) cleared and CE Marked, with availability dependent on local regulatory approvals.
GE HealthCare (Nasdaq: GEHC) reported second quarter 2026 revenues of $5.3 billion, up 5.7% year-over-year, with organic revenue growth* of 3.5%. Organic orders rose 11.1%, delivering a book-to-bill of 1.15x and a record backlog of $23.9 billion.
Net income attributable to GE HealthCare was $561 million (margin 10.6%) and Adjusted EBIT* was $750 million (margin 14.2%). Diluted EPS reached $1.24, up 16.5%, and Adjusted EPS* was $1.13, up 6.6%, both aided by IEEPA tariff refunds and a lower tax rate. Operating cash flow was $168 million and Free cash flow* $68 million.
Advanced Imaging Solutions and Pharmaceutical Diagnostics grew revenues 7.9% and 15.6%, respectively, while Patient Care Solutions revenues declined 13.3% with negative EBIT. The company repurchased 3.3 million shares for $200 million, declared a $0.035 dividend, and reaffirmed full-year 2026 guidance, including 3.0–4.0% organic revenue growth* and Adjusted EPS* of $4.80–$5.00.
GE HealthCare (Nasdaq: GEHC) announced that Chief Financial Officer Jay Saccaro will step down for an external role outside medical technology. George Newcomb, currently Controller and Chief Accounting Officer, has been appointed interim CFO. Saccaro will remain through August 14, 2026 to support a smooth transition while the company conducts a search for a permanent successor.
GE HealthCare also released preliminary, unaudited second quarter 2026 results. The company expects total revenues of $5.295 billion, up 5.7% year over year, and Organic revenue* of $5.182 billion, up 3.5%. The company expects year-over-year growth in diluted EPS and Adjusted EPS* above its prior expectation and reaffirmed full-year 2026 guidance issued on April 29, 2026. Complete Q2 results will be reported on July 29, 2026, followed by an earnings call at 8:30 am ET.
GE HealthCare (Nasdaq: GEHC) announced MIM Anyware, a web-based remote access platform that provides secure, healthcare system-controlled access to the full MIM software portfolio without local installation. Authorized users can review and process imaging data from virtually any location, supporting multidisciplinary collaboration and clinical decision-making across departments.
MIM Anyware enables multiple users such as physicians, physicists and dosimetrists to join the same session, perform clinical processing, deploy workflows and review registrations and dose in real time. According to GE HealthCare, this aims to streamline cross-functional collaboration, particularly in oncology workflows from consultations and referrals to tumor board discussions and education. The company also highlighted complementary MIM offerings, including MIM Maestro for reirradiation and composite dose assessment and MIM Contour ProtégéAI+ 2.0 with new MR Brain and updated CT Male Pelvis auto-contouring models, as part of a vendor-neutral software portfolio spanning multiple clinical specialties.
GE HealthCare (Nasdaq: GEHC) and Catholic Health on Long Island announced a 10-year strategic Care Alliance valued at approximately $500 million. The partnership covers more than 1,300 new technology assets, spanning imaging, diagnostics, AI-enabled tools, cloud and digital solutions across over 40 Catholic Health sites.
The alliance includes system-wide modernization in cardiology, oncology, neurology and women’s health, a multivendor service and maintenance agreement, and deployment of AI-powered platforms such as Imaging 360. About 50% of equipment additions are scheduled within the first three years, with the structure expected to generate capital savings for Catholic Health.
GE HealthCare (NASDAQ:GEHC) and Mayo Clinic announced the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) collaboration, a theranostics study for patients with advanced prostate cancer. It explores imaging- and biomarker-guided personalization of radioligand therapy, including adapting treatment duration based on individual disease response.
The study uses GE HealthCare’s StarGuide SPECT/CT and MIM Software’s MIM LesionID Pro to link imaging, clinical outcomes and blood biomarkers, aiming to develop predictive markers, support adaptive treatment decisions, expand access to theranostic care and investigate next-generation StarGuide GX SPECT/CT technology at Mayo Clinic’s Rochester campus.
GE HealthCare (Nasdaq: GEHC) will announce its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026.
Management will host a conference call and live webcast at 8:30 a.m. ET / 7:30 a.m. CT, with materials and replay available on the GE HealthCare investor relations website.
GE HealthCare (Nasdaq: GEHC) declared a cash dividend of $0.035 per share for the second quarter of 2026. The dividend is payable on August 14, 2026 to shareholders of record as of July 24, 2026.
GE HealthCare (GEHC) introduced Allia upgrade pathways to modernize select legacy Innova and Discovery interventional image guiding systems without major construction or full replacement. The upgrades aim to extend room lifetimes, improve workflow efficiency, expand interoperability, and support long-term operational and sustainability goals.
Depending on configuration and regulations, options may include AI-enabled CleaRecon DL, 3DStent, OmnifyXR Interventional Suite, Embo ASSIST AI, Medis Quantitative Flow Ratio, AVVIGO+ IVUS platform, plus Tube Watch and OnWatch Predict services to help reduce unplanned downtime. Upgrades are available where Allia IGS and Allia IGS Pulse are sold.